PL2576541T3 - Pochodne aminopirymidyny jako modulatory lrrk2 - Google Patents
Pochodne aminopirymidyny jako modulatory lrrk2Info
- Publication number
- PL2576541T3 PL2576541T3 PL11724168.7T PL11724168T PL2576541T3 PL 2576541 T3 PL2576541 T3 PL 2576541T3 PL 11724168 T PL11724168 T PL 11724168T PL 2576541 T3 PL2576541 T3 PL 2576541T3
- Authority
- PL
- Poland
- Prior art keywords
- aminopyrimidine derivatives
- lrrk2 modulators
- lrrk2
- modulators
- aminopyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35153010P | 2010-06-04 | 2010-06-04 | |
US201161482455P | 2011-05-04 | 2011-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2576541T3 true PL2576541T3 (pl) | 2016-10-31 |
Family
ID=44465374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11724168.7T PL2576541T3 (pl) | 2010-06-04 | 2011-06-01 | Pochodne aminopirymidyny jako modulatory lrrk2 |
Country Status (31)
Country | Link |
---|---|
US (2) | US8354420B2 (pl) |
EP (2) | EP3075730B1 (pl) |
JP (1) | JP5713367B2 (pl) |
KR (1) | KR101531448B1 (pl) |
CN (2) | CN105837519A (pl) |
AR (1) | AR081577A1 (pl) |
AU (1) | AU2011260323A1 (pl) |
BR (1) | BR112012030820B1 (pl) |
CA (1) | CA2797947C (pl) |
CL (1) | CL2012003293A1 (pl) |
CO (1) | CO6620050A2 (pl) |
CR (1) | CR20120591A (pl) |
CY (1) | CY1117719T1 (pl) |
DK (1) | DK2576541T3 (pl) |
EA (1) | EA201291220A1 (pl) |
EC (1) | ECSP12012326A (pl) |
ES (1) | ES2577829T3 (pl) |
HK (1) | HK1181758A1 (pl) |
HR (1) | HRP20160771T1 (pl) |
HU (1) | HUE029196T2 (pl) |
IL (1) | IL222686A0 (pl) |
MA (1) | MA34299B1 (pl) |
MX (1) | MX2012014158A (pl) |
PE (1) | PE20130235A1 (pl) |
PL (1) | PL2576541T3 (pl) |
PT (1) | PT2576541T (pl) |
RS (1) | RS54865B1 (pl) |
SG (1) | SG185641A1 (pl) |
SI (1) | SI2576541T1 (pl) |
WO (1) | WO2011151360A1 (pl) |
ZA (1) | ZA201208589B (pl) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
HUE046617T2 (hu) * | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
BR112014011850B1 (pt) * | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
EP3121173A1 (en) * | 2011-11-29 | 2017-01-25 | F. Hoffmann-La Roche AG | Aminopyrimidine derivatives as lrrk2 modulators |
CA2850705C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
BR112014012822A8 (pt) * | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
WO2013164323A1 (en) * | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
MX363118B (es) * | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
EP2968327A4 (en) * | 2013-03-14 | 2016-09-28 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
US9850216B2 (en) | 2013-08-06 | 2017-12-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
AU2015210554A1 (en) * | 2014-01-29 | 2016-07-07 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3778604A1 (en) * | 2015-02-13 | 2021-02-17 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2017023899A1 (en) | 2015-08-02 | 2017-02-09 | H. Lee Moffitt Cancer Center & Research Institute | Inhibitors of ack1/tnk2 tyrosine kinase |
WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
BR112018071093A2 (pt) * | 2016-04-15 | 2019-01-29 | Epizyme Inc | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo |
KR20230107407A (ko) | 2016-06-16 | 2023-07-14 | 데날리 테라퓨틱스 인크. | 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서피리미딘-2-일아미노-1h-피라졸 |
USD815942S1 (en) | 2016-10-13 | 2018-04-24 | Pepsico, Inc. | Beverage ingredient cartridge or pod or the like |
KR101923852B1 (ko) * | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CA3083022A1 (en) | 2017-11-21 | 2019-05-31 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
EP3727377B1 (en) | 2017-12-20 | 2024-01-31 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
CN111989327A (zh) | 2018-02-05 | 2020-11-24 | 奥克梅斯公司 | 用于治疗疼痛的化合物 |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
CN112888460A (zh) * | 2018-10-16 | 2021-06-01 | 达纳-法伯癌症研究所有限公司 | Lrkk2的野生型及突变型的降解剂 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
MX2022011674A (es) * | 2020-03-21 | 2022-12-15 | Arvinas Operations Inc | Compuestos a base de indazol y metodos de uso asociados. |
CN111732548B (zh) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |
JP2023545566A (ja) | 2020-10-20 | 2023-10-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法 |
CN117355507A (zh) | 2021-03-23 | 2024-01-05 | 哈利亚治疗公司 | 用作lrrk2激酶抑制剂的嘧啶衍生物 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
DE69943247D1 (de) | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
JPH11335373A (ja) * | 1998-05-25 | 1999-12-07 | Taisho Pharmaceut Co Ltd | アリールメチレンピペリジノピリミジン誘導体 |
US6172222B1 (en) | 1998-06-08 | 2001-01-09 | American Home Products Corporation | Diaminopyrazoles |
US6458823B1 (en) | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
MY133159A (en) | 1999-08-13 | 2007-10-31 | Vertex Pharma | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
EA005423B1 (ru) | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
ES2542326T3 (es) | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03005001A (es) | 2000-12-05 | 2003-09-05 | Vertex Pharma | Inhibidores de n- terminal c-jun cinasas (jnk) y otras proteinas cinasas. |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
ATE430742T1 (de) | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
BR0116411A (pt) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビター |
RS94703A (en) | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
WO2003000186A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
CA2451128A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
EP2090571B1 (de) | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1480977A2 (en) * | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Substituted aryl compounds for treatment of disease |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
CA2514612A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
US7687531B2 (en) | 2003-05-21 | 2010-03-30 | Bayer Cropscience Ag | Iodopyrazolyl carboxanilides |
CA2531490A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
EP1648887A1 (en) | 2003-07-30 | 2006-04-26 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
WO2005111016A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
CA2578349A1 (en) | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
NZ555474A (en) | 2004-12-17 | 2010-10-29 | Astrazeneca Ab | 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors |
JP2008524330A (ja) * | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | ピラゾロ[1,5−A]ピリミジンアデノシンA2a受容体アンタゴニスト |
EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
DE102005008310A1 (de) | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
JP2008540391A (ja) | 2005-05-05 | 2008-11-20 | アストラゼネカ アクチボラグ | ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用 |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
EA200800755A1 (ru) | 2005-09-07 | 2008-10-30 | Лаборатуар Сероно С.А. | Ikk ингибиторы, предназначенные для лечения эндометриоза |
EP1934200A1 (en) | 2005-09-15 | 2008-06-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
MX2008016007A (es) | 2006-06-15 | 2009-01-16 | Boehringer Ingelheim Int | 2-anilino-4-aminoalquilenoaminopirimidinas. |
WO2007149789A2 (en) | 2006-06-22 | 2007-12-27 | Applera Corporation | Conversion of target specific amplification to universal sequencing |
EP2041132A2 (en) * | 2006-07-06 | 2009-04-01 | Boehringer Ingelheim International GmbH | New compounds |
WO2008016675A1 (en) | 2006-08-01 | 2008-02-07 | Praecis Pharmaceuticals Incorporated | P38 kinase inhibitors |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
US20080194575A1 (en) | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
EA200970512A1 (ru) | 2006-11-27 | 2009-12-30 | Арес Трейдинг С.А. | Лечение по поводу множественной миеломы |
AU2007333394C1 (en) | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
WO2008079719A1 (en) | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
WO2008077885A2 (en) | 2006-12-22 | 2008-07-03 | Boehringer Ingelheim International Gmbh | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
MX2009011090A (es) * | 2007-04-18 | 2009-11-02 | Pfizer Prod Inc | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. |
TW200846344A (en) | 2007-04-25 | 2008-12-01 | Astrazeneca Ab | Chemical compounds |
MX2009013262A (es) | 2007-06-08 | 2010-01-25 | Bayer Cropscience Sa | Derivados de heterociclil-pirimidinil-amino fungicidas. |
KR20100049068A (ko) | 2007-07-17 | 2010-05-11 | 리겔 파마슈티칼스, 인크. | Pkc 억제제로서의 시클릭 아민 치환된 피리미딘디아민 |
EP2205603B1 (en) | 2007-09-28 | 2014-01-15 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
JP5548130B2 (ja) | 2007-10-09 | 2014-07-16 | ダウ アグロサイエンシィズ エルエルシー | 殺虫性ピリミジニルアリールヒドラゾン |
CA2704599C (en) | 2007-11-16 | 2015-05-12 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
WO2009071535A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
NZ587589A (en) | 2008-02-15 | 2012-10-26 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
WO2009127642A2 (en) | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
BRPI0911688A2 (pt) | 2008-07-31 | 2015-07-28 | Genentech Inc | "compostos de pirimidina, composições e métodos de uso" |
WO2010024430A1 (ja) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-ジアミノピリミジン化合物 |
JP2012501981A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 殺菌剤としてのヘテロ環置換アニリノピリミジン類 |
WO2010025831A1 (de) | 2008-09-03 | 2010-03-11 | Bayer Cropscience Ag | Heterozyklisch substituierte anilinopyrimidine als fungizide |
US20100144722A1 (en) | 2008-09-03 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds as gata modulators |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
JP2012501983A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 4−アルキル−置換ジアミノピリミジン類 |
TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
EP3255047B1 (en) | 2009-01-06 | 2021-06-30 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
EP2419423A1 (en) | 2009-04-14 | 2012-02-22 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US20120142667A1 (en) | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
EP2440548A1 (en) | 2009-06-10 | 2012-04-18 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
US20120172384A1 (en) | 2009-06-18 | 2012-07-05 | Mihiro Sunose | Heterocyclylaminopyrimidines as kinase inhibitors |
WO2010146132A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
EA021437B1 (ru) | 2009-09-29 | 2015-06-30 | Глэксо Груп Лимитед | Соединения, ингибирующие lrrk2 киназную активность |
CA2780892C (en) | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
BR112014011850B1 (pt) * | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
EP3121173A1 (en) * | 2011-11-29 | 2017-01-25 | F. Hoffmann-La Roche AG | Aminopyrimidine derivatives as lrrk2 modulators |
BR112014012822A8 (pt) * | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
-
2011
- 2011-06-01 CA CA2797947A patent/CA2797947C/en active Active
- 2011-06-01 CN CN201610187015.2A patent/CN105837519A/zh active Pending
- 2011-06-01 AU AU2011260323A patent/AU2011260323A1/en not_active Abandoned
- 2011-06-01 US US13/150,929 patent/US8354420B2/en active Active
- 2011-06-01 PE PE2012002269A patent/PE20130235A1/es not_active Application Discontinuation
- 2011-06-01 DK DK11724168.7T patent/DK2576541T3/en active
- 2011-06-01 EP EP16155153.6A patent/EP3075730B1/en active Active
- 2011-06-01 CN CN201180027409.7A patent/CN103038230B/zh active Active
- 2011-06-01 RS RS20160475A patent/RS54865B1/sr unknown
- 2011-06-01 EP EP11724168.7A patent/EP2576541B1/en active Active
- 2011-06-01 SG SG2012084794A patent/SG185641A1/en unknown
- 2011-06-01 PT PT117241687T patent/PT2576541T/pt unknown
- 2011-06-01 MX MX2012014158A patent/MX2012014158A/es active IP Right Grant
- 2011-06-01 MA MA35439A patent/MA34299B1/fr unknown
- 2011-06-01 EA EA201291220A patent/EA201291220A1/ru unknown
- 2011-06-01 KR KR1020137000111A patent/KR101531448B1/ko active IP Right Grant
- 2011-06-01 WO PCT/EP2011/059009 patent/WO2011151360A1/en active Application Filing
- 2011-06-01 PL PL11724168.7T patent/PL2576541T3/pl unknown
- 2011-06-01 BR BR112012030820-3A patent/BR112012030820B1/pt active IP Right Grant
- 2011-06-01 JP JP2013512883A patent/JP5713367B2/ja active Active
- 2011-06-01 SI SI201130857A patent/SI2576541T1/sl unknown
- 2011-06-01 HU HUE11724168A patent/HUE029196T2/en unknown
- 2011-06-01 ES ES11724168.7T patent/ES2577829T3/es active Active
- 2011-06-03 AR ARP110101920A patent/AR081577A1/es unknown
-
2012
- 2012-10-23 CO CO12188550A patent/CO6620050A2/es not_active Application Discontinuation
- 2012-10-25 IL IL222686A patent/IL222686A0/en unknown
- 2012-11-14 ZA ZA2012/08589A patent/ZA201208589B/en unknown
- 2012-11-22 CR CR20120591A patent/CR20120591A/es unknown
- 2012-11-26 CL CL2012003293A patent/CL2012003293A1/es unknown
- 2012-12-04 EC ECSP12012326 patent/ECSP12012326A/es unknown
- 2012-12-12 US US13/712,015 patent/US8802674B2/en active Active
-
2013
- 2013-08-01 HK HK13108971.1A patent/HK1181758A1/zh unknown
-
2016
- 2016-06-30 HR HRP20160771TT patent/HRP20160771T1/hr unknown
- 2016-07-01 CY CY20161100609T patent/CY1117719T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160771T1 (hr) | Derivati aminopirimidina kao modulatori za lrrk2 | |
HK1187605A1 (en) | Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2 | |
HK1200820A1 (zh) | 作為 調節劑的吡唑氨基嘧啶衍生物 | |
AP2948A (en) | Thienopyrmidinedione derivatives as TRPA1 modulators | |
HK1182594A1 (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5- | |
ZA201209117B (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
HK1166081A1 (en) | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators | |
ZA201209029B (en) | Novel pyrimidine derivatives | |
HK1201836A1 (en) | Novel pyrrole derivatives | |
EP2542075A4 (en) | Fluorouracil DERIVATIVES | |
GB2490849B (en) | Di-aspirin derivatives | |
HK1174625A1 (en) | Pyrrazolopyridine derivatives | |
HUP1000243A2 (en) | 8-hidroxy-quinoline derivatives | |
GB201106796D0 (en) | Pyrrole derivatives | |
ZA201209248B (en) | Amido-tropane derivatives | |
IL220983A0 (en) | 2-aldoximino-5-fluoropyrimidine derivatives |